Search clinical trials for: Ramucirumab Paclitaxel

Total 4173 results

Roswell Park Cancer Institute
National Cancer Institute (NCI); Novartis

Withdrawn

Dovitinib Lactate, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Solid Tumors or Pancreatic Cancer

Unspecified Adult Solid Tumor, Protocol Specific | Duct Cell Adenocarcinoma of the Pancreas | Recurrent Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer

United States
Lee's Pharmaceutical Limited

Not yet recruiting

Phase III Study of Socazolimab as First-Line Treatment in Persistent, Recurrent, or Metastatic Cervical Cancer

Cervical Cancer
Sichuan University

Not yet recruiting

Low-dose Radiation Combined With Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma
AIO-Studien-gGmbH
Celgene Corporation; ClinAssess GmbH

Completed

First-line Treatment of Metastatic Pancreatic Cancer With Nab-paclitaxel and Gemcitabine (ALPACA)

Adenocarcinoma of the Pancreas | Metastatic Pancreatic Cancer

Germany
Sun Yat-sen University

Unknown

Induction Chemotherapy in Young Patients With Locoregionally Advanced Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma | Children

China
Momenta Pharmaceuticals, Inc.

Terminated

M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer

Metastatic Pancreatic Cancer

United States, Canada
Peking University

Unknown

Nab-paclitaxel Plus S-1(AS) Versus Nab-paclitaxel Plus Gemcitabine(AG) in Patients With Advanced Pancreatic Cancer (ASAGPAC)

Pancreatic Cancer

China
Georgetown University

Terminated

Study of Gemcitabine and Abraxane for Pancreas Cancer

Pancreatic Cancer

United States
Pfizer

Terminated

Randomized Ph 2 Trial Of Paclitaxel/Carboplatin /Bevacizumab + PF-3512676 And P/C/B Alone In Advanced Nonsquamous NSCLC

Carcinoma, Non-Small-Cell Lung

United States
Women's Hospital School Of Medicine Zhejiang University
Akeso

Not yet recruiting

Cadonilimab Plus Nab -Paclitaxel for Patients With Recurrent, or Metastatic Cervical Cancer Resistant to Immune Checkpoint Inhibitors

Cervical Cancer | Uterine Cervical Neoplasms | Cancer of Cervix | Uterine Cervical Cancer | Cervical Neoplasms | Cancer of the Uterine Cervix
Peking University Third Hospital

Not yet recruiting

Comparative Clinical Study of Drug-coating Balloon Strategy and Drug-eluting Stent Strategy (Kissing-DCB)

Coronary Artery Disease

China
Sun Yat-sen University

Completed

Efficacy and Toxicity of Paclitaxel, Cisplatin Combined With Sindilimab in NACT for Locally Advanced Cervical Cancer

Cervical Cancer | Chemotherapy Effect | Neoadjuvant Therapy | Programmed Cell Death 1 Receptor / Antagonists & Inhibitors

China
Boston Scientific Corporation

Terminated

A Phase 1 / 2 Dose Escalation Study of Locally-Administered OncoGel™ in Subjects With Recurrent Glioma

Brain Neoplasms | Glioblastoma Multiforme

United States
Beijing Hospital

Completed

Clinical Trial on Safety and Efficacy of Drug-coated Balloon in Treatment of Coronary Bifurcation Lesions (BJDCB-BIF)

Coronary Disease

China
Third Military Medical University

Unknown

Paclitaxel-binding Albumin and Cisplatin as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer

Bladder Cancer

China
Montefiore Medical Center
National Cancer Institute (NCI)

Completed

Paclitaxel and GEM 231 in Treating Patients With Recurrent or Refractory Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Fondazione Sandro Pitigliani

Completed

EFficacy and Impact on Function of Two Different Doses of Nab-paclitaxEl in Elderly With advanCed breasT Cancer (EFFECT)

Breast Cancer

Italy
GlaxoSmithKline

Completed

Study of Pazopanib and Paclitaxel in Advanced Non-small Cell Lung Cancer

Lung Cancer, Non-Small Cell

United States, United Kingdom
Imperial College London
GlaxoSmithKline

Completed

[18F]Fluciclatide-PET, Pazopanib and Paclitaxel in Ovarian Cancer (PAZPET-1)

Ovarian Neoplasm

United Kingdom
Tianjin Medical University Cancer Institute and...

Unknown

Trial of Concurrent Chemoradiotherapy for Locally Advanced Esophageal Cancer

Esophageal Cancer

China
Loyola University
GlaxoSmithKline

Withdrawn

Pazopanib and Paclitaxel for Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Paclitaxel Plus L-778,123 in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphomas

Lymphoma | Unspecified Adult Solid Tumor, Protocol Specific

United States
Achieve Life Sciences

Terminated

Comparison of Safety and Efficacy of TOCOSOL(R) Paclitaxel Versus Taxol(R) for Treatment of Metastatic Breast Cancer

Breast Neoplasm

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers

Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8 | Stage III Gallbladder Cancer AJCC v8 | Stage IIIA Gallbladder Cancer AJCC v8 | Stage IIIB Gallbladder Cancer AJCC v8 | Unresectable Extrahepatic... and other conditions

United States
Jiangsu Healthy Life Innovation Medical Technology...

Not yet recruiting

Clinical Study of Tumor Treating Fields Combined With Gemcitabine and Albumin-bound Paclitaxel in the First-line Treatment of Locally Advanced Pancreatic Cancer

Locally Advanced Pancreatic Cancer

China
Chinese PLA General Hospital

Completed

An Open-label, Phase I/II Study of the Pan-immunotherapy in Patients With Relapsed/Refractory Ovarian Cancer

Ovarian Cancer

China
BioNumerik Pharmaceuticals, Inc.
Lantern Pharma Inc. became Sponsor of Tavocept (BNP7787) IND 051014 as of...

Completed

Phase 3 Study of Tavocept Versus Placebo in Patients With Newly Diagnosed or Relapsed Advanced Primary Adenocarcinoma of the Lung Treated With Docetaxel or Paclitaxel Plus Cisplatin

Non-small Cell Lung Cancer

Poland, Russian Federation, Bulgaria, United States, Romania, Ukraine
Panbela Therapeutics, Inc.

Completed

Study of SBP-101 Combined With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer

Pancreatic Cancer Metastatic | Pancreatic Cancer Stage IV | Stage IV Pancreatic Cancer

United States, Australia
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

SHR-1701 in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Chinese PLA General Hospital

Completed

Phase 2 Trial of Nab-paclitaxel Plus S-1 vs Gemcitabine Plus Cisplatin as 1-line Chemotherapy of Patients With Local Advanced and/or Metastatic Transitional Cell Carcinoma of Urothelial Tract

Carcinoma, Transitional Cell

China
Chinese PLA General Hospital

Unknown

Phase 2 Trial of Gemcitabine vs S-1 vs Gemcitabine Plus Nab-paclitaxel as Adjuvant Chemotherapy of Post-operative Pancreatic Cancer Patients

Cancer of Pancreas

China
University of California, San Francisco
Celgene Corporation

Completed

Nab-paclitaxel (Abraxane), Gemcitabine, and Capecitabine (Xeloda) for Pancreatic Adenocarcinoma

Adenocarcinoma | Pancreatic Neoplasms | Pancreatic Cancer

United States
Biotheus Inc.

Recruiting

A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC

TNBC

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Recruiting

A Study to Evaluate the Efficacy and Safety of SG001 in Combination With Nab-Paclitaxel in Patients With Advanced Triple-Negative Breast Cancer (TNBC)

Triple Negative Breast Cancer

China
Samsung Medical Center

Recruiting

Prospective, Multicenter, Non-randomized, Single Arm Clinical Trial to Evaluate the Safety and Efficacy of e-PTFE Grafts Inner Surface-treated With Paclitaxel as an Access for Hemodialysis in Patients With End-stage Renal Disease.

Hemodialysis Access Failure

Korea, Republic of
Cancer Institute and Hospital, Chinese Academy...
Beijing Friendship Hospital; Chinese PLA General Hospital; Beijing Hospital

Recruiting

Sintilimab and Nab-paclitaxel in Second-line Treatment of Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma

Advanced Gastric and Gastro-esophageal Junction Adenocarcinoma

China
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Completed

A Study of KN046 in Subjects With Locally Advanced or Metastatic Triple-negative Breast Cancer

Triple-negative Breast Cancer

China
ETOP IBCSG Partners Foundation
Breast International Group

Completed

Schedules of Nab-Paclitaxel in Metastatic Breast Cancer (SNAP)

Metastatic Breastcancer

Spain, Ireland, Italy, Switzerland, Slovenia, Belgium
Grupo Espanol de Investigacion en Sarcomas

Completed

Trial of Nab-paclitaxel in Patients With Desmoid Tumors and Multiply Relapsed/Refractory Desmoplastic Small Round Cell Tumors and Ewing Sarcoma (ABRADES)

Sarcoma | Sarcoma, Ewing | Desmoid | Tumor, Desmoplastic Small Round Cell, Adult | Tumor, Desmoplastic Small Round Cell, Childhood

Spain
Academisch Medisch Centrum - Universiteit van Amsterdam...
Celgene Corporation

Completed

The Addition of Nab-paclitaxel (Abraxane) to First Line Treatment of Metastasized Oesophagogastric Carcinoma (ACTION) (ACTION)

Esophageal Cancer | Toxicity

Netherlands
Centre de Recherche de l'Institut Universitaire...
Canadian Institutes of Health Research (CIHR); Boston Scientific Corporation

Terminated

Sealing Moderate Coronary Saphenous VEin Graft Lesions With Paclitaxel-Eluting Stents (VELETI II)

Coronary Artery Bypass Grafting

Canada
Taizhou Hospital

Unknown

Paclitaxol Every 2 Week Versus Paclitaxol Every 1 Week in the Adjuvant Treatment of Breast Cancer (PATEN)

Breast Cancer | Paclitaxel | Cyclophosphamide | Epirubicin
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Paclitaxel and BMS-214662 in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Arkadiusz Z. Dudek, MD
Bristol-Myers Squibb; Eli Lilly and Company; HealthPartners Institute Regions...

Terminated

Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma

Mesothelioma, Malignant

United States
Akeso

Recruiting

AK112 in Combination With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer

Advanced Squamous Non Small Cell Lung Cancer

China
Sichuan University

Recruiting

Safety and Efficacy of Neoadjuvant Immunochemotherapy in Elderly Patients With Resectable Esophageal Cancer

Esophageal Cancer

China
Guangdong Provincial People's Hospital

Recruiting

Neoadjuvant Almonertinib Followed by Chemo-immunotherapy in II-IIIB EGFR-mutant NSCLC (NEOVADE)

Non Small Cell Lung Cancer | EGFR Gene Mutation

China
Tianjin Medical University Second Hospital

Recruiting

Tilelizumab Combined With Nab-Paclitaxel for High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable: a Multi-center Study

High-Risk Non-Muscle Invasive Bladder Urothelial Carcinoma

China
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

Inetetamab Combined With Anti-PD-1 Monoclonal Antibody and Albumin-Bound Paclitaxel for HER2+ Metastatic Breast Cancer

Breast Cancer

China
Guangdong Provincial People's Hospital

Recruiting

Neoadjuvant Immunotherapy in EGFR-mutant Localized NSCLC (NEOTIDE)

Non-small Cell Lung Cancer | EGFR Activating Mutation

China

Search clinical trials for: Ramucirumab Paclitaxel

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Rwanda

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations